Eli Lilly’s stock dips as Alzheimer’s drug delayed by surprise FDA panel meeting

The FDA is seeking to further understand topics related to evaluating the safety and efficacy of the drug, including results in patients who have taken it and the efficacy implications of the trial design.

Source link

Related Articles

Back to top button